{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:06:46Z","timestamp":1791245206027,"version":"4.1.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T00:00:00Z","timestamp":1714435200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Non-Hodgkin\u2019s lymphoma (NHL) encompasses a diverse group of lymphoma subtypes with a wide range in disease course. Previous studies show that hypogammaglobulinemia in treatment-na\u00efve patients is associated with poorer survival in high grade B-cell non-Hodgkin\u2019s lymphomas, though it is not known how this applies across all B-cell lymphoid malignancies.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a retrospective study of immunoglobulin levels and clinical outcomes including survival, hospitalization, and infection rates in patients diagnosed with B-cell non-Hodgkin lymphomas of all grades at our institution.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Two-hundred twenty-three adults (aged = 18 years) with available pre-treatment IgG levels were selected, with hypogammaglobulinemia defined as IgG&amp;lt; 500 mg\/mL. For this analysis, we grouped DLBCL (n=90), Primary CNS (n=5), and Burkitt lymphoma (n=1) together as high-grade, while CLL (n=52), mantle cell (n=20), marginal zone (n=25), follicular (n=21), and Waldenstrom macroglobulinemia (n=5) were low-grade. The incidence of hypogammaglobulinemia in our cohort of both high and low-grade lymphoma patients was 13.5% (n=30). Across all NHL subtypes, individuals with baseline IgG&amp;lt; 500 mg\/dL showed an increased rate of hospitalization (4.453, CI: 1.955-10.54, p= 0.0005) and higher mortality (3.325, CI: 1.258, 8.491, p= 0.013), yet no association in number of infections when compared with those with IgG=500 mg\/dL. There was a higher hospitalization rate (3.237, CI: 1.77-6.051, p=0.0017) in those with high-grade lymphoma with hypogammaglobulinemia when compared with low-grade. There was no statistically significant difference in individuals who were alive after three years in those with baseline IgG&amp;lt;500 mg\/dL.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>Our study is the first to analyze incidence of hypogammaglobulinemia at the time of diagnosis of NHL as a potential biomarker of interest for future outcomes including hospitalization and infection.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fimmu.2024.1334899","type":"journal-article","created":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T04:22:25Z","timestamp":1714450945000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Baseline immunoglobulin G and immune function in non-Hodgkin lymphoma: a retrospective analysis"],"prefix":"10.3389","volume":"15","author":[{"given":"Danielle","family":"Brazel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Grant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Cabal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Pin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Pinter-Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,4,30]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404780","article-title":"Absolute lymphocyte counts predicts response to chemotherapy and survival in diffuse large B-cell lymphoma","volume":"21","author":"Kim","year":"2007","journal-title":"Leukemia"},{"key":"B2","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1111\/j.1365-2141.2006.06232.x","article-title":"Absolute lymphocyte count predicts overall survival in follicular lymphomas","volume":"134","author":"Siddiqui","year":"2006","journal-title":"Br J Haematol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.112","article-title":"The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma","volume":"25","author":"Wilcox","year":"2011","journal-title":"Leukemia"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.4084\/mjhid.2021.018","article-title":"Prognostic impact of baseline immunologic profile in aggressive B-cell non-hodgkin's lymphomas","volume":"13","author":"Ramadan","year":"2021","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.24245","article-title":"Immunoglobulin subclass levels in patients with non-Hodgkin lymphoma","volume":"124","author":"Biggar","year":"2009","journal-title":"Int J Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.5577.5577","article-title":"Does hypogammaglobulinemia at diagosis effects survival and infection risk in chronic lymphocytic leukemia (CLL)","volume":"128","author":"Atilla","year":"2016","journal-title":"Blood"},{"key":"B7","article-title":"Natural history of hypogammaglobulinemia in patients with follicular lymphoma and the impact of anti-CD20-based therapy","volume":"130","author":"Fischer","year":"2017","journal-title":"Blood"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-122737","article-title":"Prevalence and the impact of hypogammaglobulinemia in newly diagnosed, untreated diffuse large B cell lymphoma","volume":"134","author":"Singh","year":"2019","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1832673","article-title":"The prognostic roles of hypogammaglobulinemia and hypocomplementemia in newly diagnosed diffuse large B-cell lymphoma","volume":"62","author":"Pan","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V90.6.2188.2188_2188_2195","article-title":"IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2009-06-225979","article-title":"Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell-mediated B-cell cytotoxicity","volume":"115","author":"M\u00f6ssner","year":"2010","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1159\/000381524","article-title":"Obinutuzumab (GA101) for the treatment of chronic lymphocytic leukemia and other B-cell non-hodgkin's lymphomas: a glycoengineered type II CD20 antibody","volume":"38","author":"Goede","year":"2015","journal-title":"Oncol Res Treat"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.177.1.362","article-title":"The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20","volume":"177","author":"Teeling","year":"2006","journal-title":"J Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2011.08966.x","article-title":"Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma","volume":"156","author":"Barth","year":"2012","journal-title":"Br J Haematology"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2012.11.011","article-title":"Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections","volume":"13","author":"Casulo","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B18","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s12185-015-1798-9","article-title":"Kinetics of hematogones in bone marrow samples from patients with non-Hodgkin lymphomas treated with rituximab-containing regimens: a flow cytometric study","volume":"102","author":"Carulli","year":"2015","journal-title":"Int J Hematol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl141","article-title":"High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complication","volume":"17","author":"Cabanillas","year":"2006","journal-title":"Ann Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2015.10.013","article-title":"Risk of secondary hypogammaglobulinaemia after Rituximab and Fludarabine in indolent non-Hodgkin lymphomas: A retrospective cohort study","volume":"39","author":"De Angelis","year":"2015","journal-title":"Leuk Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcu094","article-title":"Hypogammaglobulinaemia after rituximab treatment-incidence and outcomes","volume":"107","author":"Makatsori","year":"2014","journal-title":"Qjm"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.2010058","article-title":"The impact of anti-CD20-based therapy on hypogammaglobulinemia in patients with follicular lymphoma","volume":"63","author":"Fischer","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"B23","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/j.1600-0609.2008.01165.x","article-title":"Risk factors for infection in haematology patients treated with rituximab","volume":"82","author":"Kanbayashi","year":"2009","journal-title":"Eur J Haematol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2014.11.009","article-title":"Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease","volume":"57","author":"Roberts","year":"2015","journal-title":"J Autoimmun"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.2174\/1574892811666160129110614","article-title":"Incidence of profound hypogammaglobulinemia and infection rate in lymphoma patients following the combination of chemotherapy and rituximab","volume":"11","author":"Filanovsky","year":"2016","journal-title":"Recent Pat Anticancer Drug Discovery"},{"key":"B26","doi-asserted-by":"publisher","first-page":"5022","DOI":"10.3390\/cancers14205022","article-title":"Infectious complications of targeted therapies in children with leukemias and lymphomas","volume":"14","author":"Kyriakidis","year":"2022","journal-title":"Cancers"},{"key":"B27","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1111\/myc.12621","article-title":"Invasive fungal infections in paediatric patients treated with macromolecular immunomodulators other than tumour necrosis alpha inhibitors","volume":"60","author":"Kyriakidis","year":"2017","journal-title":"Mycoses"},{"key":"B28","article-title":"Serum immunoglobulins in non-Hodgkin's lymphoma patients","volume":"34","author":"Planinc-Peraica","year":"2010","journal-title":"Coll Antropol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-020-00769-8","article-title":"Lymphoproliferative disease in CVID: a report of types and frequencies from a US patient registry","volume":"40","author":"Yakaboski","year":"2020","journal-title":"J Clin Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2005.12.013","article-title":"Infectious complications of chronic lymphocytic leukemia","volume":"33","author":"Wadhwa","year":"2006","journal-title":"Semin Oncol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/(ISSN)1097-0142","article-title":"Serum immunoglobulins in B-chronic lymphocytic leukemia. Natural history and prognostic significance","volume":"61","author":"Rozman","year":"1988","journal-title":"Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.937872","article-title":"Genomic crossroads between non-Hodgkin's lymphoma and common variable immunodeficiency","volume":"13","author":"Guevara-Hoyer","year":"2022","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-022-01368-5","article-title":"Lymphoma as an exclusion criteria for CVID diagnosis revisited","volume":"43","author":"Allain","year":"2023","journal-title":"J Clin Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1334899\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,30]],"date-time":"2024-04-30T04:22:28Z","timestamp":1714450948000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2024.1334899\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,30]]},"references-count":33,"alternative-id":["10.3389\/fimmu.2024.1334899"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2024.1334899","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,30]]},"article-number":"1334899"}}